Format

Send to

Choose Destination
Nat Commun. 2014 Jun 17;5:4051. doi: 10.1038/ncomms5051.

2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy.

Author information

1
1] Human Genetics, Genome Institute of Singapore, 60 Biopolis Street 02-01, Singapore 138672, Singapore [2] Saw Swee Hock School of Public Health, National University of Singapore, MD3, 16 Medical Drive, Singapore 117597, Singapore [3].
2
1] Department of Surgery, University of California at San Francisco (UCSF), San Francisco, California 94143, USA [2] Department of Biosciences and Nutrition, Karolinska Institutet and University Hospital, SE-171 77 Stockholm, Sweden [3].
3
Human Genetics, Genome Institute of Singapore, 60 Biopolis Street 02-01, Singapore 138672, Singapore.
4
Faculty of Medicine, University of Southampton, University Hospital Southampton, Southampton SO16 6YD, UK.
5
1] Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Postbus 90203, 1006 BE Amsterdam, The Netherlands [2] Division of Molecular Pathology, Netherlands Cancer Institute, Postbus 90203, 1006 BE Amsterdam, The Netherlands.
6
1] Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK [2] Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK.
7
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
8
Division of Molecular Pathology, Netherlands Cancer Institute, Postbus 90203, 1006 BE Amsterdam, The Netherlands.
9
Department of Surgery, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
10
Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, 5th floor, West Wing, Medical Building 181, Melbourne, Victoria 3010, Australia.
11
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Level 1, 723 Swanston Street, Melbourne, Victoria 3010, Australia.
12
1] Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Level 1, 723 Swanston Street, Melbourne, Victoria 3010, Australia [2] Department of Health Science and Services, Graduate School of Public Health, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea.
13
1] University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054 Erlangen, Germany [2] Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, California 90095, USA.
14
University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054 Erlangen, Germany.
15
Institute of Human Genetics, Friedrich Alexander University Erlangen-Nuremberg, Schlossplatz 4, 91054 Erlangen, Germany.
16
Department of Oncology, University of Helsinki and Helsinki University Central Hospital, FI-00029 HUS Helsinki, Finland.
17
Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Haartmaninkatu 8, FI-00029 Helsinki, Finland.
18
Department of Clinical Genetics, University of Helsinki and Helsinki University Central Hospital, Haartmaninkatu 8, FI-00029 Helsinki, Finland.
19
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm SE-17177, Sweden.
20
Department of Oncology-Pathology, Karolinska Institutet, Stockholm SE-17177, Sweden.
21
1] School of Medicine, Institute of Clinical Medicine, Oncology, University of Eastern Finland, Yliopistonranta 1C, FI-70211 Kuopio, Finland [2] Biocenter Kuopio, Cancer Center of Eastern Finland, University of Eastern Finland, FI-70211 Kuopio, Finland [3] Cancer Center, Kuopio University Hospital, Puijonlaaksontie 2, 70210 Kuopio, Finland.
22
1] School of Medicine, Institute of Clinical Medicine, Oncology, University of Eastern Finland, Yliopistonranta 1C, FI-70211 Kuopio, Finland [2] Cancer Center, Kuopio University Hospital, Puijonlaaksontie 2, 70210 Kuopio, Finland [3] Jyväskylä Central Hospital, Keskussairaalantie 19, 40620 Jyväskylä, Finland.
23
Department of Genetics, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland 4006, Australia.
24
1] Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Level 1, 723 Swanston Street, Melbourne, Victoria 3010, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, St Andrews Place East, East Melbourne, Victoria 3002, Australia.
25
Department of Oncology, St Vincent's Hospital Melbourne, 9 Princes Street, Fitzroy, Victoria 3065, Australia.
26
1] Vesalius Research Center (VRC), VIB, Herestraat 49, 3000 Leuven, Belgium [2] Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Herestraat 49, 3000 Leuven, Belgium.
27
Multidisciplinary Breast Center, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
28
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
29
1] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany [2] Department of Cancer Epidemiology/Clinical Cancer Registry, University Clinic Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany [3] Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
30
1] Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Level 1, 723 Swanston Street, Melbourne, Victoria 3010, Australia [2] Cancer Epidemiology Centre, Cancer Council Victoria, 1 Rathdowne Street, Melbourne, Victoria 3053, Australia.
31
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1975 San Pablo Street, Los Angeles, California 90033, USA.
32
University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, Hawaii 96813, USA.
33
1] Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Ullernchausseen 70, N-0310 Oslo, Norway [2] K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway [3] Department of Clinical Molecular Biology (EpiGen), Medical Division, Akershus University Hospital, Sykehusveien 25, 1478 Lørenskog, Norway.
34
1] Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Ullernchausseen 70, N-0310 Oslo, Norway [2] K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.
35
Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, Oulu University Hospital, Aapistie 5A, FI-90220 Oulu, Finland.
36
Laboratory of Oncology, Oulu University Hospital, University of Oulu, Kajaanintie 50, FI-90220 Oulu, Finland.
37
1] Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1 × 5 [2] Department of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, Ontario, Canada M5S 1A8.
38
1] Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1 × 5 [2] Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, 155 College Street, Toronto, Ontario, Canada M5T 3M7.
39
Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1 × 5.
40
Research, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1 × 5.
41
1] Department of Human Genetics, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands [2] Department of Pathology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
42
Department of Surgical Oncology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
43
Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075EA Rotterdam, The Netherlands.
44
Department of Clinical Genetics, Erasmus University Medical Center, Groene Hilledijk 301, 3075EA Rotterdam, The Netherlands.
45
Molecular Genetics of Breast Cancer, DKFZ, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
46
1] Molecular Genetics of Breast Cancer, DKFZ, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany [2] Institute of Human Genetics, Pontificia University Javeriana, Carrera 7, Bogotá 11001000, Colombia.
47
Frauenklinik der Stadtklinik Baden-Baden, D-7570 Baden-Baden, Germany.
48
Institute of Pathology, Städtisches Klinikum Karlsruhe, Moltkestrasse 90, 76133 Karlsruhe, Germany.
49
1] Institute of Biomedical Sciences, Academia Sinica, Academia Road Nankang, Taipei 115, Taiwan [2] College of Public Health, China Medical University, No. 91, Hsueh-Shih Road, Taichung 40402, Taiwan.
50
Institute of Biomedical Sciences, Academia Sinica, Academia Road Nankang, Taipei 115, Taiwan.
51
Taiwan Biobank, Academia Sinica, Academia Road Nankang, Taipei 115, Taiwan.
52
Department of Surgery, Changhua Christian Hospital, No. 135, Nanhsiao Street, Changhua 500, Taiwan.
53
1] Cancer Research Initiatives Foundation, Sime Darby Medical Centre, 1 Jalan SS 12/1A, Subang Jaya47500, Selangor, Malaysia [2] Breast Cancer Research Unit, Faculty of Medicine, University Malaya Cancer Research Institute, University Malaya, Lembah Pantai, 59100 Kuala Lumpur, Malaysia.
54
Breast Cancer Research Unit, Faculty of Medicine, University Malaya Cancer Research Institute, University Malaya, Lembah Pantai, 59100 Kuala Lumpur, Malaysia.
55
Department of Oncology, Faculty of Medicine, University Malaya, Lembah Pantai, 59100 Kuala Lumpur, Malaysia.
56
Department of Preventive Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
57
Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1-1 Kanokoden Chikusa-ku, Nagoya 464-8681, Aichi, Japan.
58
Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, Nagoya 464-8681, Aichi, Japan.
59
1] Department of Preventive Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 110-799, Korea [2] Department of Biomedical Sciences, Seoul National University Graduate School, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea.
60
Department of Biomedical Sciences, Seoul National University Graduate School, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea.
61
Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 110-799, Korea.
62
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK.
63
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, 171 77 Stockholm, Sweden.

Abstract

Large population-based registry studies have shown that breast cancer prognosis is inherited. Here we analyse single-nucleotide polymorphisms (SNPs) of genes implicated in human immunology and inflammation as candidates for prognostic markers of breast cancer survival involving 1,804 oestrogen receptor (ER)-negative patients treated with chemotherapy (279 events) from 14 European studies in a prior large-scale genotyping experiment, which is part of the Collaborative Oncological Gene-environment Study (COGS) initiative. We carry out replication using Asian COGS samples (n=522, 53 events) and the Prospective Study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) study (n=315, 108 events). Rs4458204_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n=2,641, 440 events, combined allelic hazard ratio (HR)=1.81 (1.49-2.19); P for trend=1.90 × 10(-9)). Such survival-associated variants can represent ideal targets for tailored therapeutics, and may also enhance our current prognostic prediction capabilities.

PMID:
24937182
PMCID:
PMC4082638
DOI:
10.1038/ncomms5051
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substance, Grant support

Publication types

MeSH terms

Substance

Grant support

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center